FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233045625> ?p ?o ?g. }

• W4233045625 abstract "Event Abstract Back to Event Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform Yaoying Wu1, Tao Sun1, Caitlin Wong1, Vincent P. Conticello2 and Joel H. Collier1 1 University of Chicago, Department of Surgery, United States 2 Emory College, Department of Chemistry, United States Introduction: Peptide self-assembly has been widely explored for biomaterials applications, including cell delivery, drug delivery, and vaccine platforms. It has been previously demonstrated that epitope-bearing β-sheet fibrillizing peptides can elicit strong and specific antibody responses without supplemental immune adjuvants, making them an attractive platforms for vaccine development[1]. However, β-sheet fibrillizing peptides lack structural precision, and the kinetics of their assembly and disassembly are difficult to control. To address these shortcomings, we now report the design of a new self-assembly platform based on peptides that fold and assemble into α-helical nanofibers. This folding strategy allows for greater structural control and tunable rates of assembly and disassembly. We expect this control will be crucial in optimizing the materials’ trafficking and engagement of specific immune cells in vivo. The self-assembled peptide fiber was designed to incorporate both the universal CD4+ T cell epitope (PADRE, aKXVAAWTLKAa, where “X” is cyclohexylalanine, and “a” is D-alanine)[2] and a B-cell epitope (PEPvIII, LEEKKGNYVVTDH) targeting the epidermal growth factor receptor class III variant (EGFRvIII)[3], a tumor-specific receptor present in a significant proportion of glioblastomas and other human cancers. Both T cell and B cell epitopes were covalently linked to the helical peptide with C-terminal extensions. The antibody responses elicited by the epitope-bearing fiber were found by ELISA to be epitope-specific, dependent upon self-assembly, and comparable in titers to that raised by epitope peptide delivered in complete Freund’s adjuvant (CFA). Materials and Methods: Peptides were synthesized as previously reported[1]. The morphology of the self-assembled fiber was studied using both circular dichroism (CD) and transmission electron microscopy (TEM). Immunizations were given in sterile PBS to female C57BL/6 mice subcutaneously. After 4 weeks, each mouse was boosted with one-half the primary dose. Mice in the CFA group were boosted with incomplete Freund’s adjuvant (IFA). Antibody titers were determined using ELISA. Results and Discussion: The Form-I peptide developed by Conticello and co-workers (QARILEADAEILRAYARILEAHAEILRAQ)[4] self-assembled into cylindrical α-helical fibers in our hands. With N-terminal extension of the epitope sequence, the modified Form peptide could still self-assemble into α-helical fibers, regardless of the hydrophobicity of the epitopes, according to TEM and CD. (Fig. 1) Although the morphology of PADRE-Form peptide appeared to be different (Fig. 1 c), the peptide fiber formed with PEPvIII-Form (Fig. 1 b) and mixing PEPvIII-Form and PADRE-Form (Fig. 1 d) both exhibited similar morphology to that of the Form peptide fiber (Fig. 1 a). The immunization study showed that PEPvIII peptide did not elicit strong antibody responses without being conjugated to the fibrillizing peptide. (Fig. 2, PEPvIII group) While PEPvIII- specific was antibodies were raised in mice immunized with only PEPvIII-Form peptide to about titer 2 after boost (Fig. 2, PEPvIII-Form group), the antibody titer was significantly higher in the mice immunized with PEPvIII-Form/PADRE-Form (Fig. 2. PEPvIII-Form/PADRE-Form Group), comparable to the peptide delivered with CFA (Fig. 2, PEPvIII/CFA group). These results indicated that the immunogenicity of the materials relied upon both the self-assembling fibrillar peptide and also T cell help. Fig. 1. The TEM images and CD graphs of a) Form peptide fiber, b) PEPvIII-Form peptide fiber, c) PADRE-Form peptide fiber, d) PEPvIII-Form/PADRE-Form peptide fiber Fig. 2. Anti-PEPvIII antibody responses observed in different mice groups. Half of primary immunization dose was given to each mice as boost injections Conclusion: Epitope-bearing Form peptides self-assembled into α-helical fibers, with morphologies similar to the unmodified peptide. Specific antibody responses against an EGF receptor epitope relevant to the treatment of glioblastoma were raised without adjuvant. Additionally, the co-assembly of PADRE-Form augmented the response to a level similar to mice receiving a strong adjuvant, CFA. These results indicate that this platform may be useful in the development of self-adjuvanting vaccines. NIH/NIAID 5R01AI118182References:[1] Rudra, J. S.; Tian, Y. F.; Jung, J. P.; Collier, J. H. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 622–7[2] Pompano, R. R.; Chen, J.; Verbus, E. A.; Han, H.; Fridman, A.; McNeely, T.; Collier, J. H.; Chong, A. S. Adv Healthc Mater 2014, 3, 1898–908[3] Choi, B.; Archer, G.; Mitchell, D.; Heimberger, A.; McLendon, R.; Bigner, D.; Sampson, J. Brain Pathology 2009, 19, 713-23[4] Egelman, E. H.; Xu, C.; DiMaio, F.; Magnotti, E.; Modlin, C.; Yu, X.; Wright, E.; Baker, D.; Conticello, V. P. Structure 2015, 23, 280–9 Keywords: in vivo, biomaterial, nanofiber, Polypeptide Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: New Frontier Oral Topic: Biomaterials in immune response Citation: Wu Y, Sun T, Wong C, Conticello VP and Collier JH (2016). Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.00152 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Yaoying Wu Tao Sun Caitlin Wong Vincent P Conticello Joel H Collier Google Yaoying Wu Tao Sun Caitlin Wong Vincent P Conticello Joel H Collier Google Scholar Yaoying Wu Tao Sun Caitlin Wong Vincent P Conticello Joel H Collier PubMed Yaoying Wu Tao Sun Caitlin Wong Vincent P Conticello Joel H Collier Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W4233045625 created "2022-05-12" @default.
• W4233045625 creator A5033830330 @default.
• W4233045625 creator A5034814459 @default.
• W4233045625 creator A5076032158 @default.
• W4233045625 creator A5079758236 @default.
• W4233045625 creator A5087887706 @default.
• W4233045625 date "2016-01-01" @default.
• W4233045625 modified "2023-09-30" @default.
• W4233045625 title "Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform" @default.
• W4233045625 doi "https://doi.org/10.3389/conf.fbioe.2016.01.00152" @default.
• W4233045625 hasPublicationYear "2016" @default.
• W4233045625 type Work @default.
• W4233045625 citedByCount "0" @default.
• W4233045625 crossrefType "journal-article" @default.
• W4233045625 hasAuthorship W4233045625A5033830330 @default.
• W4233045625 hasAuthorship W4233045625A5034814459 @default.
• W4233045625 hasAuthorship W4233045625A5076032158 @default.
• W4233045625 hasAuthorship W4233045625A5079758236 @default.
• W4233045625 hasAuthorship W4233045625A5087887706 @default.
• W4233045625 hasBestOaLocation W42330456251 @default.
• W4233045625 hasConcept C171250308 @default.
• W4233045625 hasConcept C185592680 @default.
• W4233045625 hasConcept C192562407 @default.
• W4233045625 hasConcept C2779281246 @default.
• W4233045625 hasConcept C55493867 @default.
• W4233045625 hasConcept C91129048 @default.
• W4233045625 hasConceptScore W4233045625C171250308 @default.
• W4233045625 hasConceptScore W4233045625C185592680 @default.
• W4233045625 hasConceptScore W4233045625C192562407 @default.
• W4233045625 hasConceptScore W4233045625C2779281246 @default.
• W4233045625 hasConceptScore W4233045625C55493867 @default.
• W4233045625 hasConceptScore W4233045625C91129048 @default.
• W4233045625 hasLocation W42330456251 @default.
• W4233045625 hasOpenAccess W4233045625 @default.
• W4233045625 hasPrimaryLocation W42330456251 @default.
• W4233045625 hasRelatedWork W1971602529 @default.
• W4233045625 hasRelatedWork W1983452903 @default.
• W4233045625 hasRelatedWork W2046221528 @default.
• W4233045625 hasRelatedWork W2103521023 @default.
• W4233045625 hasRelatedWork W2111187674 @default.
• W4233045625 hasRelatedWork W2150335795 @default.
• W4233045625 hasRelatedWork W2473351640 @default.
• W4233045625 hasRelatedWork W2479739315 @default.
• W4233045625 hasRelatedWork W3080709939 @default.
• W4233045625 hasRelatedWork W3120698274 @default.
• W4233045625 hasVolume "4" @default.
• W4233045625 isParatext "false" @default.
• W4233045625 isRetracted "false" @default.
• W4233045625 workType "article" @default.